Dose Insider / Glossary / SUMMIT

SUMMITTirzepatide for heart failure with preserved ejection fraction

Updated November 20, 2026 · 3 min read · Packer et al., N Engl J Med 2025

SUMMIT is the trial of tirzepatide in people with obesity and heart failure with preserved ejection fraction, the form of heart failure in which the heart's ejection fraction is 50% or more.

9.9%Tirzepatide, worse heart failure or CV death
Worse heart failure or CV deathSUMMIT, median 104 weeks, % of patientsTirzepatide9.9%Placebo15.3%Worse heart failure or CVdeathSUMMIT, median 104 weeks, % of patientsTirzepatide9.9%Placebo15.3%

Hazard ratio 0.62; driven by fewer worsening heart failure events.

On this page

It enrolled 731 people and gave them tirzepatide, up to 15 mg a week, or placebo for at least 52 weeks. Over a median of 104 weeks, cardiovascular death or a worsening heart failure event occurred in 9.9% on tirzepatide against 15.3% on placebo. It was published in the New England Journal of Medicine in 2025.1

How the trial was run

SUMMIT was international, double-blind and placebo-controlled. Participants had heart failure, an ejection fraction of at least 50% and a body mass index of at least 30. They were assigned in equal numbers, 364 to tirzepatide and 367 to placebo. Tirzepatide was given once a week under the skin, with the dose raised up to 15 mg, the top dose on the Zepbound and Mounjaro labels.1,2

It had two main outcomes. The first was a combination of death from cardiovascular causes or a worsening heart failure event, both checked by an independent committee and counted from the first one. The second was the change at 52 weeks in the clinical summary score of the Kansas City Cardiomyopathy Questionnaire, or KCCQ-CSS, a 0 to 100 measure of symptoms and physical limits.1

What it found

Packer et al., 2025.1

How to read the result

The benefit came almost entirely from fewer episodes of worsening heart failure, not from fewer deaths. In absolute terms, 5.4 fewer people in every 100 had a main-outcome event over about two years, roughly one for every 19 people treated, a figure we calculated from the published percentages. The rise in KCCQ score shows people also felt better and did more.1

The authors' conclusion was that tirzepatide lowered the risk of cardiovascular death or worsening heart failure compared with placebo and improved health status in people with this kind of heart failure and obesity.1

SUMMIT went a step beyond STEP-HFpEF, the earlier trial of semaglutide 2.4 mg in the same condition. That trial measured symptoms and walking distance over one year in 529 people, and its KCCQ score rose by 16.6 points against 8.7.3 SUMMIT, longer and larger, also counted heart failure events. The two drugs were not compared with each other.

Side effects

Adverse events, mainly in the stomach and gut, led 6.3% on tirzepatide to stop the drug, against 1.4% on placebo.1 On the Zepbound label's weight trials, nausea was reported by 25% to 29% across doses against 8% on placebo.2 Our Zepbound side effects timeline shows when they tend to start and fade.

Is it on the label?

The Zepbound label's approved uses are weight management and moderate to severe obstructive sleep apnea in adults with obesity. Heart failure is not listed as a separate use in the version we read, revised August 2026.2 People with this condition who take Zepbound do so under the weight indication.

Limits

The trial enrolled only people with obesity, so it says nothing about heart failure of this kind in people of lower weight. It was funded by Eli Lilly, the maker of tirzepatide.1

Sources

  1. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity (SUMMIT). N Engl J Med 2025;392:427-437. Funded by Eli Lilly; NCT04847557. doi:10.1056/NEJMoa2410027
  2. ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 1 and 6.1. accessdata.fda.gov
  3. Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity (STEP-HFpEF). N Engl J Med 2023;389:1069-1084. doi:10.1056/NEJMoa2306963

Related analyses

Log your weight, symptoms and walks and see how they change together.

Open Dose Insider